Longitude Capital, a private investment firm that focuses on venture growth investments in drug development and medical technology, promoted Sandip K. Agarwala to Managing Director.
Mr. Agarwala joined Longitude in 2013 and focuses on structured investments in both biotechnology and medical device companies.
He was responsible for the creation of the firm’s royalty investment vehicle, CrownWheel Partners, and its associated infrastructure.
Looking forward, Mr. Agarwala will continue to lead Longitude’s royalty investment strategy.
Led by Managing Director Patrick Enright, Longitude is a private investment firm that focuses on venture growth investments in drug development and medical technology. Besides traditional venture capital investments, the firm’s investment team also proactively searches for “special situations”, such as spin-outs, recapitalizations, PIPEs, royalty monetizations and structured transactions, across both privately-held and publicly-traded companies.
Founded in 2006, Longitude Capital consists of ten investment professionals and operates bi-coastally with offices in Menlo Park, CA and Greenwich, CT. Recent investments include Allergen Research Corporation, Amarin Corporation, AqueSys, California CryoBank, Cadence Pharmaceuticals, Civitas Therapeutics, Collegium Pharmaceutical, Corcept Therapeutics, Esperion Therapeutics, Jazz Pharmaceuticals, NxStage Medical, Precision Dermatology, Twelve and Venus Concept.
It has over $700m in assets under management, and most recently raised $385m for its second fund, Longitude Venture Partners II, L.P., in 2012.